# **UC Irvine**

# **UC Irvine Previously Published Works**

#### **Title**

S6. The scientific basis of chemoprevention in humans: What's important?

### **Permalink**

https://escholarship.org/uc/item/7nj487x9

### **Journal**

European Journal of Cancer Supplements, 6(3)

#### **ISSN**

1359-6349

#### **Author**

Meyskens, FL

### **Publication Date**

2008-03-01

#### DOI

10.1016/s1359-6349(08)70198-8

## **Copyright Information**

This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed

# Session 2: Cancer prevention: The scientific-epidemiological base

## S6. The scientific basis of chemoprevention in humans: What's important?

F.L. Meyskens\*

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, USA

A large amount of experimental data indicates that the carcinogenic process can be blocked or interrupted. An equally abundant lexicon of epidemiologic observations suggests that dietary factors are associated with a lowered risk of cancer, either in general or related to a specific organ site cancer. However, except for the prevention of breast cancer the data in humans remains unconvincing, despite many phase III randomized trials. Among the major reasons, at least two this investigator, include:

- Incorrect or overenthusiastic extrapolation of epidemiologic data to clinical trials.
- Poorly constructed phase II biomarker trials that do not usefully inform the design of phase III trials.
- Failure to select doses of intervention agents bases on modulation of relevant markers in organ of interest.
- Failure to develop a dose of drug that modulates relevant biomarkers without producing limiting toxicity.
  Alternative approaches to these conundrums and dilemmas will be proposed.